Seif Al Abri, Amina Al-Jardani, Padmamohan J. Kurup, Unyeong Go, Daniela Maria Cirillo, Eskild Petersen, Hannah Monica Yesudian Dias, Michael Wilson, Dominik Zenner, Muhammad Akhtar, Thomas B. Schön, Fatma Al Yaquobi, Ziad A. Memish, Christian Wejse, Thereza Kasaeva, Amal Al Maani, Troels Lillebaek, Simon Tiberi, Delia Goletti, Ali Al Maqbali, Faryal Khamis, Giovanni Battista Migliori, and Justin T Denholm
Aim: The purpose of this viewpoint is to summarize the advantages and constraints of the tools and strategies available for reducing the annual incidence of tuberculosis (TB) by implementing the World Health Organization (WHO) End TB Strategy and the linked WHO TB Elimination Framework, with special reference to Oman. Methods: The case-study was built based on the presentations and discussions at an international workshop on TB elimination in low incidence countries organized by the Ministry of Health, Oman, which took place from September 5 to September 7, 2019, and supported by the WHO and European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Results: Existing tools were reviewed, including the screening of migrants for latent TB infection (LTBI) with interferon-gamma release assays, clinical examination for active pulmonary TB (APTB) including chest X-rays, organization of laboratory services, and the existing centres for mandatory health examination of pre-arrival or arriving migrants, including examination for APTB. The need for public-private partnerships to handle the burden of screening arriving migrants for active TB was discussed at length and different models for financing were reviewed. Conclusions: In a country with a high proportion of migrants from high endemic countries, screening for LTBI is of high priority. Molecular typing and the development of public-private partnerships are needed. (C) 2020 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. Funding Agencies|WHOWorld Health Organization; ESCMID; Qiagen; Cepheid; Advanced Healthcare Solutions; PfizerPfizer; MSD; QIAGEN Sciences Inc.